INS and Hypoglycemia: Moreover, there was a consistent and significant reduction in hypoglycaemia risk with insulin glargine compared with NPH insulin for both overall symptomatic (11%, p = 0.0006) and nocturnal (26%, p < 0.0001) hypoglycaemic events (24,28).